Stay updated with breaking news from Database Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.
– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab –– Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 month...
Patients treated with the three-drug combination had a 27% lower risk of progression or death compared to those on the two immunotherapy drugs.
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
08.09.2022 - Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX), nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in ...